C109P.LA: Tusamitamab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant

Catalog No.: C109P.LA | **Product Name:** Tusamitamab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant

Tusamitamab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant. The research grade tusamitamab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C109P.LA
Product Name	Tusamitamab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Carcinoembryonic Antigen-related Cell Adhesion Molecule 5
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 LALAPG Fc Silent Mutant
Source/Host	The anti-human CEACAM5 monoclonal antibody tusamitamab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade tusamitamab biosimilar specifically binds to the CEACAM5 protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by tusamitamab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Tusamitamab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Tusamitamab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is tusamitamab biosimilar research grade? Tusamitamab is a humanized IgG1-kappa monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) which is overexpressed in tumors including non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and is an attractive target for therapies based on CAR-T cell or/and ADCs. Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC) combining a humanized monoclonal antibody and a potent cytotoxic maytansinoid derivative (DM4) inhibiting microtubule assembly. Tusamitamab biosimilar uses the same protein sequences as the therapeutic antibody tusamitamab.

This L234A/L235A/P329G (LALAPG) triple mutant variant in human IgG1 constant region eliminates binding to Fc gamma receptors and C1q complement. It offers a fully Fc-silent framework for evaluating target-specific binding to CEACAM5 without non-specific Fc-mediated effector immune responses.